Dual-targeted CAR T-cell therapy shows promise in patients with treatment-resistant multiple myeloma
A first-in-human study by Mass General Brigham Cancer Institute investigators found that a chimeric antigen receptor (CAR) T-cell therapy called TriPRIL reduced or eliminated signs of cancer in 12 of 15 patients with relapsed ...
Nov 18, 2026
0
7







